Tokyo, Japan

Takehiro Yatomi

This inventor holds 3 USPTO granted patents. Top assignees: Mochida Pharmaceutical Co., Ltd., Osaka Bioscience Institute, Other. Active years: 2003-2006.


% Patents Active = 66.7

Average Co-Inventor Count = 1.8

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2003-2006

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Takehiro Yatomi: Innovator in Medical Treatments

Introduction

Takehiro Yatomi is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of medical treatments, particularly in the area of autoimmune diseases. With a total of 3 patents to his name, Yatomi's work has the potential to impact many lives.

Latest Patents

Yatomi's latest patents include a method of treating graft versus host disease by administration of a Fas antagonist. This invention focuses on methods of preventing and treating diseases where apoptosis is involved. Another notable patent is for preventives and remedies for autoimmune demyelinating diseases. This method involves administering an effective amount of a Fas antagonist to patients in need, utilizing substances that suppress Fas-Fas ligand binding.

Career Highlights

Throughout his career, Yatomi has worked with reputable organizations such as Mochida Pharmaceutical Co., Ltd. and Osaka Bioscience Institute. His experience in these companies has allowed him to develop innovative solutions for complex medical issues.

Collaborations

Yatomi has collaborated with esteemed colleagues, including Shigekazu Nagata and Takashi Suda. These partnerships have further enriched his research and development efforts.

Conclusion

Takehiro Yatomi's contributions to medical science through his patents and collaborations highlight his dedication to improving treatment options for autoimmune diseases. His innovative approaches continue to pave the way for advancements in healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…